126 related articles for article (PubMed ID: 38264577)
1. The Efficacy and Safety of Sofosbuvir and Daclatasvir Treatment in Children and Adolescents With Thalassemia and Hepatitis C Virus Infection.
Samadder RK; Ray G; Dutta S; Hazra A; Sadhukhan P; Chowdhury A; Ray R; Ahammed SM
J Clin Exp Hepatol; 2024; 14(3):101310. PubMed ID: 38264577
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.
Mehta R; Kabrawala M; Nandwani S; Desai P; Bhayani V; Patel S; Parekh V
J Clin Exp Hepatol; 2018 Mar; 8(1):3-6. PubMed ID: 29743790
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.
Abdel-Aziz AM; Ibrahim MA; El-Sheikh AA; Kamel MY; Zenhom NM; Abdel-Raheim S; Abdelhaleem H
J Clin Exp Hepatol; 2018 Mar; 8(1):15-22. PubMed ID: 29743792
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
6. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract][Full Text] [Related]
9. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
10. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.
Abdel Ghaffar TY; El Naghi S; Abdel Gawad M; Helmy S; Abdel Ghaffar A; Yousef M; Moafy M
J Viral Hepat; 2019 Feb; 26(2):263-270. PubMed ID: 30380158
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Poordad F; Shiffman ML; Ghesquiere W; Wong A; Huhn GD; Wong F; Ramji A; Shafran SD; McPhee F; Yang R; Noviello S; Linaberry M;
Antivir Ther; 2019; 24(1):35-44. PubMed ID: 30382942
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
[TBL] [Abstract][Full Text] [Related]
14. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Ahmed S; Hassan E; Gomaa A; Esamat G; Ramadan A; Ahmed M; Elsayed A; A Wahsh E
Curr Drug Saf; 2023; 18(2):207-213. PubMed ID: 35538812
[TBL] [Abstract][Full Text] [Related]
15. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M
Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.
Ahmed OA; Elsebaey MA; Fouad MHA; Elashry H; Elshafie AI; Elhadidy AA; Esheba NE; Elnaggar MH; Soliman S; Abd-Elsalam S
Infect Drug Resist; 2018; 11():441-445. PubMed ID: 29628768
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
